USA – Egret Therapeutics, a New York-based clinical-stage biotherapeutics company, raised an undisclosed amount in Pre-A funding.
The round was led by Fascinate Therapeutics with participation from Turret Capital Management.
Led by CEO Dr. Daniel Chai, Egret Therapeutics is a clinical-stage biotherapeutics company focused on developing products to address areas of clinical unmet need in neurological diseases.The company intends to use the funds to support the clinical development of its lead asset EGT-101 for the treatment of Delayed Cerebral Ischemia (DCI) post subarachnoid hemorrhage and to further pipeline development. Egret was founded by Turret Capital along with Dr. Michael Lim, Chairperson of Neurosurgery at Stanford Medical Center, and Dr. Christopher Jackson, Assistant Professor of Neurosurgery at Johns Hopkins Medical Center. 22/02/2022
Led by CEO Dr. Daniel Chai, Egret Therapeutics is a clinical-stage biotherapeutics company focused on developing products to address areas of clinical unmet need in neurological diseases.The company intends to use the funds to support the clinical development of its lead asset EGT-101 for the treatment of Delayed Cerebral Ischemia (DCI) post subarachnoid hemorrhage and to further pipeline development. Egret was founded by Turret Capital along with Dr. Michael Lim, Chairperson of Neurosurgery at Stanford Medical Center, and Dr. Christopher Jackson, Assistant Professor of Neurosurgery at Johns Hopkins Medical Center. 22/02/2022
